About Revolution Medicines
Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main products are RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.
Redwood City, CaliforniaHeadquarters
2014Year Founded
$219.8MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees
Benefits
Company Equity
Risks
EQRx acquisition may pose integration challenges and cultural clashes.
$600M public stock offering could lead to shareholder dilution.
Focus on RAS-addicted cancers limits market scope and increases competition risk.
Differentiation
Revolution Medicines reconfigures natural substances into best-in-class cancer therapies.
Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
Exclusive license with University of Illinois enhances their unique synthesis technology.
Upsides
Acquisition of EQRx adds over $1 billion in capital for R&D.
FDA fast-tracking supports their RAS-targeted therapy pipeline.
Growing interest in targeted cancer therapies boosts investment opportunities.
Funding
Total raised$219.84 M
Latest valuation$500.00 M
StageIPO
POST IPO EQUITY
11/30/2024$90
$56
$280.00 MSERIES A
11/30/2016$25
$125.00 M